China CEE Fund makes its first investment in biotechnology by acquiring 13.2% stake in Bioton S.A.
In 2015 China-CEE Fund acquired 13.2% of shares in Warsaw Stock Exchange listed Bioton S.A.. China-CEE Fund, advised by CEE Equity Partners acquired the shares in a series of transactions after protracted negotiations with existing shareholders. On 21st September 2015, two representatives from CEE Equity Partners, the Investment Advisor of the Fund, were appointed to the Supervisory Board of the Company.
China-CEE Fund intends to support the Management in their plan to expand into new markets with the existing product portfolio whilst developing the next generation of products for which the Company which has a skilled manufacturing base.
China-CEE Fund priorities for the future include supporting enhanced corporate governance and improved communication with the financial markets.
About Bioton S.A.
Bioton S.A. specialises in biotechnology drug development and manufacturing, with its core product recombinant human insulin being distributed across 4 continents. The company was founded in 1989 and subsequently listed on the Warsaw Stock Exchange in 2005. Bioton S.A. is based in Macierzysz, Poland and generates over 60% of its revenue from exports.